Broad researchers Matthew Meyerson and Heidi Greulich describe how they and Bayer scientists developed the first FDA-approved cancer drug to come from a Broad scientific discovery.

The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy. The approval reflects a multi-year collaboration led by Dana-Farber Cancer Institute investigators, working closely with colleagues at the Broad Institute.

Collaboration between Broad Institute and Bayer leads to new treatment for a hard-to-treat type of lung cancer.

Researchers have developed a genome-editing strategy that targets a common cause of roughly 30 percent of rare diseases and could vastly improve access to gene-editing treatments for patients.

The MacArthur Foundation supports creative people and effective institutions committed to building a more just, verdant, and peaceful world. In addition to selecting the MacArthur Fellows, we work to ...

CHICAGO, IL — November 18, 2025 — The John D. and Catherine T. MacArthur Foundation has awarded $100 million to the Broad Institute for the…

Programmable control of gene expression in specific cell types is essential for both basic discovery and therapeutic intervention, yet current strategies lack scalability across diverse cellular conte...

A single mutation in the CD36 gene, present in 17 percent of people with African ancestry, increases a person's dilated cardiomyopathy risk by 33 percent.

Metagenomic analysis of the gut microbiome of people with human immunodeficiency virus (HIV), from three distinct cohorts, revealed infection- and antiretroviral drug-linked alterations, which may con...

cSplotch compares spatial transcriptomics data across ages and regions of mouse colon tissue.

The compound, now under priority review at FDA, targets HER2 mutations in lung cancer and shrinks tumors in mice and humans.

Decisions about critical care are almost always made without access to genetic information. The authors report the application of a new method of DNA sequencing in infants in a neonatal intensive c...

FUGAsseM predicts protein function in microbiomes using coexpression patterns from metatranscriptomes and diverse community-wide data.